APA (7th ed.) Citation

Y, S., J, J., J, T., C, Y., & Q, H. (2025). The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply. The Lancet. Rheumatology, 7(7), e460. https://doi.org/10.1016/S2665-9913(25)00110-9

Chicago Style (17th ed.) Citation

Y, Shen, Jia J, Teng J, Yang C, and Hu Q. "The Use of IL-1 and IL-6 Inhibitors Should Be Prioritised in Still's Disease - Authors' Reply." The Lancet. Rheumatology 7, no. 7 (2025): e460. https://doi.org/10.1016/S2665-9913(25)00110-9.

MLA (9th ed.) Citation

Y, Shen, et al. "The Use of IL-1 and IL-6 Inhibitors Should Be Prioritised in Still's Disease - Authors' Reply." The Lancet. Rheumatology, vol. 7, no. 7, 2025, p. e460, https://doi.org/10.1016/S2665-9913(25)00110-9.